IINN vs SPRO vs INVA vs AVAV vs ABBV

For growth investors, Innoviva, Inc.

(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -53. 8% for Spero Therapeutics, Inc. (SPRO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Spero Therapeutics, Inc. (SPRO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus AeroVironment, Inc. at 108. 6x. On forward P/E, Spero Therapeutics, Inc. is actually cheaper at 3. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +99. 6%, compared to -91. 0% for Inspira Technologies Oxy B. H. N. Ltd. (IINN). Over 10 years, the gap is even starker: AVAV returned +498. 7% versus IINN's -91. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus AeroVironment, Inc. 's 1. 55β — meaning AVAV is approximately 1260% more volatile than INVA relative to the S&P 500. On balance sheet safety, AeroVironment, Inc. (AVAV) carries a lower debt/equity ratio of 7% versus 58% for Inspira Technologies Oxy B. H. N. Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innoviva, Inc.

(INVA) is pulling ahead at 18. 5% versus -53. 8% for Spero Therapeutics, Inc. (SPRO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -395. 3% for Spero Therapeutics, Inc.. Over a 3-year CAGR, SPRO leads at 150. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -43. 7% for Inspira Technologies Oxy B. H. N. Ltd. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IINN leads at 45. 1% versus -152. 9% for SPRO. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Spero Therapeutics, Inc.

(SPRO) trades at 3. 8x forward P/E versus 58. 4x for AeroVironment, Inc. — 54. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVAV: 104. 2% to $343. 60.

In this comparison, ABBV (3.

3% yield) pays a dividend. IINN, SPRO, INVA, AVAV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, IINN: -91. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IINN (Healthcare) and SPRO (Healthcare) and INVA (Healthcare) and AVAV (Industrials) and ABBV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IINN is a small-cap quality compounder stock; SPRO is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; AVAV is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while IINN, SPRO, INVA, AVAV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.